L-Phenylalanine, L-?-aspartyl-L-threonyl-L-leucyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-leucyl-L-?-glutamyl-L-isoleucyl-L-alanyl-L-seryl-L-cysteinyl-L-leucyl-L-?-glutamyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-valyl-
Squamous Cell Carcinoma of Head and Neck
IO Biotechprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
37 Active assets in the Squamous Cell Carcinoma of Head and Neck cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Akeso | Phase 4 | BB |
Capecitabine Merck Sharp & Dohme LLC | Phase 2 | BB |
LENVATINIB Salubris Biotherapeutics Inc | Phase 2 | B |
Pembrolizumab/Vibostolimab Coformulation Merck Sharp & Dohme LLC | Phase 2 | B |
Nemvaleukin Alfa Mural Oncology, Inc | Phase 2 | B |
View all 50 →
Same molecule, other indications
L-Phenylalanine, L-?-aspartyl-L-threonyl-L-leucyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-leucyl-L-?-glutamyl-L-isoleucyl-L-alanyl-L-seryl-L-cysteinyl-L-leucyl-L-?-glutamyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-valyl- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →